XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]        
Research and development revenue under collaboration agreement $ 2,004 $ 382 $ 7,316 $ 3,766
Revenue from Contract with Customer, Product and Service [Extensible List] us-gaap:InProcessResearchAndDevelopmentMember us-gaap:InProcessResearchAndDevelopmentMember us-gaap:InProcessResearchAndDevelopmentMember us-gaap:InProcessResearchAndDevelopmentMember
Operating expenses:        
Research and development $ 15,172 $ 15,488 $ 30,723 $ 29,831
General and administrative 5,322 5,845 10,598 11,848
Total operating expenses 20,494 21,333 41,321 41,679
Loss from operations (18,490) (20,951) (34,005) (37,913)
Other income (expense):        
Investment income 1,381 460 2,677 583
Other expense (6)   (6)  
Total other income, net 1,375 460 2,671 583
Net loss (17,115) (20,491) (31,334) (37,330)
Other comprehensive loss:        
Unrealized gain (loss) on marketable securities 35 (626) (456) (1,104)
Total comprehensive loss $ (17,080) $ (21,117) $ (31,790) $ (38,434)
Net loss per share:        
Net loss per share attributable to common stockholders basic $ (0.44) $ (0.57) $ (0.83) $ (1.03)
Net loss per share attributable to common stockholders diluted $ (0.44) $ (0.57) $ (0.83) $ (1.03)
Weighted-average common stock outstanding, basic 39,292,710 36,160,951 37,783,486 36,118,415
Weighted-average common stock outstanding, diluted 39,292,710 36,160,951 37,783,486 36,118,415